The phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an analysis of CELC stock now.

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are several clinical trials ...

PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of PI3K protein in cancer cells and can be used to treat certain types of breast cancer with a PIK3CA gene mutation.

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...